Haoxi Health Technology Limited (HAO) Fair Value & Analysis
Communication Services · US · Market cap $2.6M
Haoxi Health Technology Limited
HAO · US
Fair value as of: Jul 7, 2026
From 10 valuation models · updated yesterday
Fair value updated Jul 7, 2026 — revised from $26.23 to $1.28 (−95.1%) since Jun 24, 2026. Share price +25.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.8372 – $193.73 · fair‑value band $0.9017 – $2.12 · the $1.05 price screens below the $1.28 fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Haoxi Health Technology Limited (HAO) currently trades at $1.05, while our model-based Fair Value estimate is $1.28 — implying the stock looks roughly 22.2% undervalued today. We read business quality at 45/100 (below-average quality), in the Communication Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Haoxi Health Technology Limited generated revenue of $42.7M at a net margin of -6.5%. Revenue grew 41.2% year over year. It earns a return on equity of -16.0%. The balance sheet holds a net cash position of $6.6M. Fundamentals as of Jul 7, 2026
Our scenario range runs from $0.9017 (bear case) to $2.12 (bull case); at $1.05, the current price sits within that range. For context, the median of 10 Communication Services peers we cover trades at 12% fair-value upside — at 22%, HAO screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
Haoxi Health Technology Limited, through its subsidiaries, provides online marketing solutions in China. It offers online marketing solutions, including online short video marketing solutions to advertisers through its media partners; and customized marketing solutions by planning, producing, placing, and optimizing online ads to help advertisers acquire, convert, and retain consumers on various online media platforms. The company places its ads through mainstream online short video and social media platforms, such as Toutiao, Douyin, WeChat, and Sina Weibo. It serves advertiser client base primarily in the healthcare industry. Haoxi Health Technology Limited was founded in 2018 and is based in Chaoyang, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Haoxi Health Technology Limited reported revenue of $32.8M in FY2025 versus $16.2M in FY2021, a compound +19.4%/yr. Reported net income was $3.9M in FY2025, compounding +99.5%/yr from FY2021.
Is HAO fairly valued? → Check now
Similar stocks
10 more Advertising Agencies stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| AppLovin Corporation APP | $492.98 | $253.58 | -49% |
| Publicis Groupe S.A PGPEF | $103.00 | $166.23 | +61% |
| Omnicom Group OMC | $72.55 | $124.48 | +72% |
| Focus Media Information Technology Co 002027 | ¥5.39 | ¥3.34 | -38% |
| The Trade Desk, Inc TT8 | €17.05 | €18.89 | +11% |
| BlueFocus Intelligent Communications Group 300058 | ¥14.75 | ¥2.11 | -86% |
| Dentsu Group DNTUY | $19.14 | $44.72 | +134% |
| JCDecaux SE DEC | €18.41 | €20.52 | +11% |
| CyberAgent, Inc CYGIY | $3.81 | $4.28 | +12% |
| WPP plc W1PP34 | R$19.35 | R$25.96 | +34% |
Explore undervalued stocks
More undervalued Communication Services stocks →
Frequently asked questions
Is Haoxi Health Technology Limited (HAO) undervalued?
What is the fair value of HAO?
What is the quality score of HAO?
What is the revenue of Haoxi Health Technology Limited (HAO)?
What is the net profit margin of HAO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.